Desloratadine
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Desloratadine: From Allergic Rhinitis/Chronic Urticaria to Cold Urticaria
One-Sentence Summary
Desloratadine is a second-generation H1-antihistamine (specific original-indication and market license data for Germany are not available in this evidence pack). The TxGNN model predicts it may be effective for Cold Urticaria, with 3 clinical trials and 7 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no Germany license data available); desloratadine is generically classified as a second-generation antihistamine for allergic rhinitis / chronic urticaria |
| Predicted New Indication | Cold Urticaria |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L1 (3 completed Phase 4 RCTs + multiple supporting RCT publications) |
| Germany Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, desloratadine is a second-generation, non-sedating H1-receptor antagonist widely used for allergic conditions such as allergic rhinitis and chronic idiopathic urticaria. Its efficacy in histamine-mediated skin and mucosal reactions is well established in clinical practice.
Cold urticaria is a physical subtype of urticaria in which cold exposure triggers mast cell degranulation and histamine release, producing wheals identical in mechanism to other histamine-driven urticarias. Since desloratadine already blocks the H1 receptor pathway central to urticarial reactions, its mechanistic extension to cold urticaria is biologically plausible and is directly reflected in the fact that multiple prospective, dose-escalation trials have already been conducted specifically in cold urticaria populations — including studies testing standard (5 mg) versus updosed (20 mg) regimens, consistent with international urticaria treatment guidelines that recommend antihistamine updosing for refractory cases.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01444196 | Phase 4 | Completed | 30 | Dose-escalation study (5/10/20 mg) to determine dose sufficient to inhibit acquired cold urticaria symptoms |
| NCT00600847 | Phase 4 | Completed | 33 | Double-blind, placebo-controlled crossover comparing 5 mg vs. 20 mg desloratadine on experimentally induced cold urticaria lesions (thermography/volumetry) |
| NCT01940393 | Phase 4 | Completed | 150 | Evaluation of inhibitory effect of 5 antihistamines (including desloratadine) in urticaria; pharmacokinetic/pharmacodynamic comparison |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19201016 | 2009 | RCT | J Allergy Clin Immunol | Randomized, placebo-controlled crossover trial: high-dose desloratadine decreased wheal volume and improved cold-provocation thresholds vs. standard dose |
| 22242678 | 2012 | RCT | Br J Dermatol | Randomized controlled trial of H1-antihistamine dose escalation using critical temperature threshold measurement in cold urticaria |
| 15516152 | 2004 | Review | Drugs | Review of chronic urticaria aetiology, management, and current/future antihistamine-based treatment options |
| 19032340 | 2008 | Review | Allergy | Review of second-generation antihistamine efficacy in allergic rhinitis and chronic idiopathic urticaria |
| 14754651 | 2004 | Clinical study | J Dermatolog Treat | Ice-cube provocation test in 12 cold urticaria patients before/after 4 days of 5 mg desloratadine treatment showed symptom inhibition |
| 29698807 | 2018 | Case series | J Allergy Clin Immunol Pract | Description of food-dependent cold urticaria as a physical urticaria variant |
| 38025339 | 2023 | Case report | Qatar Med J | First reported case of cold-induced urticaria following black ant bite-induced anaphylaxis |
Germany Market Information
Desloratadine is currently not marketed in Germany according to this evidence pack, and no authorization records are available for listing.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is supported by strong clinical and literature evidence (3 completed Phase 4 RCTs and multiple RCT publications specifically in cold urticaria), but the Blocking data gap on TFDA-equivalent label warnings/contraindications (DG001) prevents completion of the required S1 safety pre-assessment, and the drug currently has no market authorization in Germany.
To proceed, the following is needed:
- Official product label / package insert warnings and contraindications (DG001 — Blocking)
- Confirmed mechanism of action (MOA) data via DrugBank API (DG002 — High)
- Clarification of Germany registration/market-entry status and pathway, given 0 current authorizations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.